GH
Closed
Guardant Health Inc
50.71
-1.33 (-2.56%)
Last Update: 01 Jul 2025 23:02:00
Yesterday: 52.04
Day's Range: 50.055 - 51.96
Send
sign up or login to leave a comment!
When Written:
23.92
Guardant Health Inc. is a precision oncology company that specializes in developing liquid biopsy tests for cancer diagnosis and treatment. The company was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz and is headquartered in Redwood City, California.
Guardant Health's flagship product is the Guardant360 test, which uses next-generation sequencing technology to analyze circulating tumor DNA (ctDNA) in the blood of cancer patients. The test can detect mutations in more than 70 cancer genes and is used to guide treatment decisions for advanced cancer patients.
In addition to Guardant360, the company also offers the GuardantOMNI test, which analyzes both ctDNA and RNA in the blood to identify novel biomarkers and potential drug targets. Guardant Health has partnerships with several pharmaceutical companies to use its liquid biopsy technology in clinical trials and drug development.
Guardant Health went public in October 2018 and is listed on the NASDAQ stock exchange under the ticker symbol GH. The company has a market capitalization of over $10 billion as of 2021.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Guardant Health's flagship product is the Guardant360 test, which uses next-generation sequencing technology to analyze circulating tumor DNA (ctDNA) in the blood of cancer patients. The test can detect mutations in more than 70 cancer genes and is used to guide treatment decisions for advanced cancer patients.
In addition to Guardant360, the company also offers the GuardantOMNI test, which analyzes both ctDNA and RNA in the blood to identify novel biomarkers and potential drug targets. Guardant Health has partnerships with several pharmaceutical companies to use its liquid biopsy technology in clinical trials and drug development.
Guardant Health went public in October 2018 and is listed on the NASDAQ stock exchange under the ticker symbol GH. The company has a market capitalization of over $10 billion as of 2021.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








